Valid Ghana · FDA Ghana

IKE 100 CAPSULES (Each hard gelatin capsule contains Hraconazole 100mg)

Hraconazole 100mg

FDA/SD.265-070666 Hraconazole 100mg 100mg

What it does

Fungal infection treatment

Commonly used for: Ringworm (tinea corporis), Athlete's foot (tinea pedis), Toenail fungus (tinea unguium), Fungal nail infections …

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.265-070666
Registration date
2026-07-15
Expiry date
2029-08-01
Status
Valid
Active ingredient
Hraconazole 100mg
Dosage form
Hraconazole 100mg
Strength
100mg
Pack size
-
Therapeutic class
-
Applicant / LTR
athena healthcare ltd
Country of origin
INDIA
Manufacturer location
Road No: 42, Plot No: 4232, GIDC, Sachin, Surat, Gujarat 394230, India

Source: Food and Drugs Authority · fetched 2026-07-24 04:00:05 · updated 2026-10-20 04:00:04

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Fungal infection treatment

What it treats

  • Ringworm (tinea corporis)
  • Athlete's foot (tinea pedis)
  • Toenail fungus (tinea unguium)
  • Fungal nail infections
  • Onychomycosis

How it works

Hraconazole works by stopping the growth of fungi that cause infections.

Who it's for

For adults and children over 12 years old.

Cautions

  • • Not recommended for people with liver problems or those taking certain medications.
  • • May cause side effects such as headaches, dizziness, or stomach problems.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: hraconazole

Itraconazole is an antifungal medication belonging to the triazole class, primarily used for the treatment of various fungal infections, including those caused by Candida, Aspergillus, and dermatophytes. It is available in capsule and oral solution forms and is indicated for systemic and superficial fungal infections.

Indications

  • Aspergillosis
  • Blastomycosis
  • Candidiasis (systemic and oral)
  • Coccidioidomycosis
  • Histoplasmosis
  • Onychomycosis
  • Tinea infections (dermatophyte infections)

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on the child's age and weight.

Adults: Dosage varies based on the specific infection and severity. Refer to specific guidelines for detailed dosing information.

Mechanism of action

Itraconazole works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. This inhibition occurs through the blockade of the enzyme lanosterol 14-alpha-demethylase, which is crucial for converting lanosterol to ergosterol. The resultant disruption of the fungal cell membrane leads to increased permeability and ultimately, cell death.

Pharmacodynamics

Itraconazole exhibits fungistatic and fungicidal properties depending on the concentration relative to the minimum inhibitory concentration (MIC) of the target organism. It is effective against a broad spectrum of fungi, particularly in its ability to penetrate tissues and achieve therapeutic concentrations in various body fluids.

Pharmacokinetics

Itraconazole is well absorbed from the gastrointestinal tract, though its absorption is significantly enhanced when taken with food. It undergoes extensive hepatic metabolism, primarily via cytochrome P450 3A4, leading to the formation of active metabolites. The elimination half-life is approximately 24 hours, allowing for once-daily dosing in many cases. Itraconazole is primarily excreted in urine and feces.

Contra-indications

  • Hypersensitivity to itraconazole or any component of the formulation
  • Concurrent use with certain medications such as cisapride, dofetilide, or ergot alkaloids due to the risk of serious cardiac events

Adverse effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Headache
  • Dizziness
  • Liver enzyme elevation
  • Skin rash
  • Anaphylaxis
  • Heart failure in patients with pre-existing cardiac conditions

Interactions

  • May increase plasma concentrations of certain drugs metabolized by CYP3A4, including statins, benzodiazepines, and calcium channel blockers
  • Concomitant use with drugs that have a high potential for QT prolongation should be approached with caution

Precautions

  • Use cautiously in patients with a history of liver disease, heart failure, or renal impairment
  • Monitor liver function tests periodically during therapy
  • Consider potential drug-drug interactions, especially in polypharmacy situations

Pregnancy

Category C. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether itraconazole is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

  • Capsules
  • Oral solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.